Literature DB >> 6203663

Idiosyncratic reaction to bleomycin in an epithelial tumor.

M J Inbar, M Baratz, A Figer, E Schpitzer-Reter, S Chaitchik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6203663     DOI： 10.1007/bf00401453

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  11 in total

1.  A clinical review of bleomycin--a new antineoplastic agent.

Authors:  R H Blum; S K Carter; K Agre
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

2.  Bleomycin treatment of the tumors of penis and scrotum.

Authors:  T Ichikawa; I Nakano; I Hirokawa
Journal:  J Urol       Date:  1969-12       Impact factor: 7.450

3.  Safe and effective combination chemotherapy for squamous cell carcinomas of the head and neck.

Authors:  L A Price; B T Hill
Journal:  J Laryngol Otol       Date:  1980-01       Impact factor: 1.469

4.  Combination chemotherapy in disseminated testicular cancer: the Indiana University experience.

Authors:  L H Einhorn; J P Donohue
Journal:  Semin Oncol       Date:  1979-03       Impact factor: 4.929

5.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.

Authors:  G Bonadonna; R Zucali; S Monfardini; M De Lena; C Uslenghi
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

6.  Combination radical surgery and multiple sequential chemotherapy for the treatment of advanced carcinoma of the testis (stage III).

Authors:  C Merrin; H Takita; R Weber; Z Wajsman; G Baumgartner; G P Murphy
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

7.  Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule.

Authors:  S E Vogl; B H Kaplan
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

8.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

Authors:  P S Schein; V T DeVita; S Hubbard; B A Chabner; G P Canellos; C Berard; R C Young
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

9.  Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma.

Authors:  V Rodriguez; F Cabanillas; M A Burgess; E M McKelvey; M Valdivieso; G P Bodey; E J Freireich
Journal:  Blood       Date:  1977-03       Impact factor: 22.113

10.  Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion.

Authors:  I H Krakoff; E Cvitkovic; V Currie; S Yeh; C LaMonte
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.